R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma

Prusila, Roosa; Haapasaari, Kirsi‐Maria; Marin, Katja; Pollari, Marjukka; Soini, Ylermi; Vornanen, Martine; Karjalainen–Lindsberg, Marja-Liisa; Turpeenniemi‐Hujanen, Taina; Kuittinen, Outi

doi:10.1080/0284186x.2018.1450522

Cited by 18 publications

(11 citation statements)

References 25 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…R‐CHOP appears to be an active regimen with a 10‐year PFS reported of 59% in a small retrospective cohort of patients with different stages of disease 43 . The combination of bendamustine plus rituximab has shown encouraging treatment response in a small group of adults with advanced‐stage NLPHL but the median follow‐up was relatively short 50 . Additionally, the use of bendamustine is associated with a small risk of myelodysplasia and acute leukaemia.…”

Section: Group 3: Stage Iiia With Non‐mediastinal Peripheral Nodal Di...mentioning

confidence: 99%

“…43 The combination of bendamustine plus rituximab has shown encouraging treatment response in a small group of adults with advanced-stage NLPHL but the median follow-up was relatively short. 50 Additionally, the use of bendamustine is associated with a small risk of myelodysplasia and acute leukaemia. Although the data for R-CVP in adults is scant 45 it is an attractive option as it does not use an anthracycline or bleomycin, is well tolerated, and is used extensively for other lymphoma subtypes.…”

Section: Group 3: Stage Iiia With Non-mediastinal Peripheral Nodal Di...mentioning

confidence: 99%

See 1 more Smart Citation

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

et al. 2022

View full text Add to dashboard Cite

Summary A consensus statement for the management for patients of all ages with all stages of nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) — All StAGEs — is proposed by representatives of the UK National Cancer Research Institute (NCRI) Hodgkin lymphoma study group and the Children's Cancer & Leukaemia Group. Based on current practices and published evidence, a consensus has been reached regarding diagnosis, staging and risk‐ik7 stratified management which includes active surveillance, low‐ and standard‐dose immunochemotherapy and radiotherapy.

show abstract

Section: Group 3: Stage Iiia With Non‐mediastinal Peripheral Nodal Di...mentioning

confidence: 99%

Section: Group 3: Stage Iiia With Non-mediastinal Peripheral Nodal Di...mentioning

confidence: 99%

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

et al. 2022

View full text Add to dashboard Cite

show abstract

“…A recent retrospective study explored the combination of bendamustine and rituximab (BR) in 9 patients (median age 45 years) with NLPHL, including 2 with relapsed disease following treatment with ABVD or RT (Prusila et al , ). All 9 patients had a CR.…”

Section: Treatment Of Relapsed or Refractory Disease (Table )mentioning

confidence: 99%

Modern principles in the management of nodular lymphocyte‐predominant Hodgkin lymphoma

2018

View full text Add to dashboard Cite

Summary Nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) is a unique rare subtype of Hodgkin lymphoma (HL) which differs clinically, pathologically and biologically from classic HL, warranting a nuanced approach to treatment. CD20 expression by malignant lymphocyte‐predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B‐cell lymphoma are characteristic features with important implications for treatment and follow‐up. Recognition of histopathological variant patterns is also critical, with important implications for prognosis and treatment. The optimal management for NLPHL is unclear and opinions differ as to whether treatment paradigms should be similar to, or differ from, those for classic HL. Therapy differs for early versus advanced stage disease and for frontline versus relapsed or refractory disease. Potential treatment strategies include radiotherapy, combined modality therapy, chemotherapy, rituximab and watchful waiting. Given the excellent overall survival of NLPHL, treatment choices should be geared towards reducing long‐term toxicity and optimizing survivorship. In this review, we provide an overview of the current literature and discuss modern principles in the management of NLPHL.

show abstract

“…No standard treatment has been defined for this patient group until now 5 . Activity has been demonstrated for both HL‐directed protocols and regimens commonly used in B‐cell non‐Hodgkin lymphoma (B‐NHL) 6–10 . The outcome of 84 patients with newly diagnosed advanced NLPHL treated within the randomized German Hodgkin Study Group (GHSG) HD18 study for advanced HL has been reported recently.…”

Section: Introductionmentioning

confidence: 99%

Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

et al. 2021

View full text Add to dashboard Cite

Summary We retrospectively investigated histopathological growth patterns in individuals with advanced nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) treated within the randomized HD18 study. In all, 35/60 patients (58%) presented with atypical growth patterns. Patients with atypical growth patterns more often had stage IV disease (P = 0·0354) and splenic involvement (P = 0·0048) than patients with typical growth patterns; a positive positron emission tomography after two cycles of chemotherapy (PET‐2) tended to be more common (P = 0·1078). Five‐year progression‐free survival [hazard ratio (HR) = 0·86; 95% confidence interval (CI) = 0·49–1·47] and overall survival (HR = 0·85; 95% CI = 0·49–1·51) did not differ between the groups after study treatment with PET‐2‐guided escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone). Thus, advanced NLPHL is often associated with atypical growth patterns but their prognostic impact is compensated by PET‐2‐guided escalated BEACOPP.

show abstract

R-Bendamustine in the treatment of nodular lymphocyte-predominant Hodgkin lymphoma

Cited by 18 publications

References 25 publications

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute

Modern principles in the management of nodular lymphocyte‐predominant Hodgkin lymphoma

Histopathological growth patterns in patients with advanced nodular lymphocyte‐predominant Hodgkin lymphoma treated within the randomized HD18 study: a report from the German Hodgkin Study Group

Contact Info

Product

Resources

About